Very low-dose versus standard dose radiation therapy for indolent primary cutaneous B-cell lymphomas: A retrospective study

Goyal, Amrita; Carter, Joi B.; Pashtan, Itai; Gallotto, Sara L.; Wang, Irène; Isom, S. Clay; Ng, Andrea K.; Winkfield, Karen M.

doi:10.1016/j.jaad.2017.07.053

Cited by 18 publications

(5 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More recently, few reports have investigated the role of 4 Gy in cutaneous, 17 head and neck, 25 salivary gland 26 and breast 18 localizations of MALT lymphomas, all demonstrating the efficacy of LDRT in terms of LC. We observed the same high LC rates for all different sites of MALT or nodal MZL, but with a distinction in terms of PFS.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of low-dose radiotherapy (2 Gy × 2) in the treatment of marginal zone and mucosa-associated lymphoid tissue lymphomas

Cerrato

Orlandi

Vella

et al. 2021

The British Journal of Radiology

View full text Add to dashboard Cite

Objectives: To investigate the efficacy of a schedule of low dose radiotherapy (LDRT) with 4 Gy (2 Gy x 2) in a cohort of unselected MALT or MZL patients. Methods: We retrospectively collected all patients receiving LDRT, either for cure or palliation, for a stage I–IV histologically proven MALT or MZL between 2016 and 2020. Response to LDRT was evaluated with the Lugano criteria. Local control (LC), distant relapse-free survival (DRFS), progression-free survival (PFS) and overall survival (OS) were stratified for treatment intent (curative vs palliative) and estimated by the Kaplan Meier product-limit. Results: Among 45 consecutive <>enrolled patients with a median age of 68 years (range 22–86), 26 (58%) were female. Thirty-one patients (69%) with a stage I–II disease received LDRT as first line therapy and with a curative intent. Overall response rate was 93%, with no significant difference among curative and palliative intent. With a median follow-up of 18 months, LC, DRFS, PFS and OS at 2 years were 93%, 92%, 76% and 91%, respectively, in the overall population. Patients receiving curative LDRT had a better PFS at 2 years (85% vs 54%, p < 0.01) compared to patients receiving palliative treatment. LDRT was well tolerated in all patients, without any significant acute or chronic side-effect. Conclusions: LDRT is effective and well tolerated in patients affected with MALT or nodal MZL, achieving high response rates and durable remission at 2 years. Advances in knowledge: This study shows the efficacy of LDRT in the treatment of MALT and MZL.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of low-dose radiotherapy (2 Gy × 2) in the treatment of marginal zone and mucosa-associated lymphoid tissue lymphomas

Cerrato

Orlandi

Vella

et al. 2021

The British Journal of Radiology

View full text Add to dashboard Cite

show abstract

“…Numerous guidelines have been published defining radiation dosing regimens for MF ranging from 24 to 30 Gy, 7 but small series in cutaneous B cell lymphoma have shown comparable response rates with RT of 4 to 8 Gy in 2 treatments,8, 9 a regimen frequently used in indolent follicular lymphomas. Low-dose RT represents an attractive therapeutic option for many reasons.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of low-dose radiotherapy for refractory mycosis fungoides of the face

et al. 2019

View full text Add to dashboard Cite

“…Retrospective cohorts help define the optimal dose to reduce toxicity and maintain a high response rate. No significant difference between very low dose (4–8 Gy) and standard dose (>24 Gy) has been found by Goyal et al [ 38 ] but the response rate was significantly lower in the very low dose group (4 Gy) versus standard dose (>24 Gy, median 40 Gy) in a recent study on PCMZL and PCFCL [ 39 ]. The European Society for Medical Oncology (ESMO) guidelines recommend a standard dose of 24 to 30 Gy for localized disease and a low dose of 4 Gy for the palliative treatment of disseminated disease [ 40 ].…”

Section: Indolent Pcbclmentioning

confidence: 92%

Diagnosis and Treatment of Primary Cutaneous B-Cell Lymphomas: State of the Art and Perspectives

Dumont

Battistella

Ram‐Wolff

et al. 2020

Cancers

View full text Add to dashboard Cite

Primary cutaneous B-cell lymphomas are rare entities that develop primarily in the skin. They constitute a heterogeneous group that represents around a quarter of primary cutaneous lymphomas. The 2018 update of the World Health Organization-European Organization for Research and Treatment of Cancer (WHO-EORTC) classification differentiates primary cutaneous marginal zone lymphoma and primary cutaneous follicle center lymphoma with an indolent course from primary cutaneous diffuse large B-cell lymphoma, leg type with an aggressive behavior. The broad spectrum of clinical presentations and the disease course marked by frequent relapses are diagnostic and therapeutic challenges. The classification of these diseases has been refined in recent years, which allows to better define their immunopathogenesis and specific management. In the present article, we review the main clinico-biological characteristics and the current therapeutic options of these three main subsets. Based on the recent therapeutic advances in nodal B-cell lymphomas, we focus on the development of novel treatment options applicable to primary cutaneous B-cell lymphomas, including targeted therapies, combination treatments and immunotherapeutic approaches, and cover basic, translational and clinical aspects aiming to improve the treatment of cutaneous B-cell lymphomas.

show abstract

Very low-dose versus standard dose radiation therapy for indolent primary cutaneous B-cell lymphomas: A retrospective study

Cited by 18 publications

References 6 publications

Efficacy of low-dose radiotherapy (2 Gy × 2) in the treatment of marginal zone and mucosa-associated lymphoid tissue lymphomas

Efficacy of low-dose radiotherapy (2 Gy × 2) in the treatment of marginal zone and mucosa-associated lymphoid tissue lymphomas

Efficacy of low-dose radiotherapy for refractory mycosis fungoides of the face

Diagnosis and Treatment of Primary Cutaneous B-Cell Lymphomas: State of the Art and Perspectives

Contact Info

Product

Resources

About